CEPs: What Applicants and Authorisation Holders should know!
Recommendation
20 October 2026
Copenhagen, Denmark
An ECA Course prior to the 29th APIC/CEFIC Global GMP & Regulatory API Conference
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
Due to the current situation in Europe, many applicants and marketing authorisation holders (MAHs) are increasingly asking how and to what extent "CEPs" (Certificate of Suitability of Monographs of the European Pharmacopoeia) are currently being processed and issued.
In this regard, the EDQM (European Directorate for the Quality of Medicines & HealthCare) website provides the most up-to-date information. On the one hand, the topics are mentioned that are currently being prioritized in the CEPs area. On the other hand, it comprises explanations for which measures were taken and which processes were changed or newly established as a result of the corona pandemic.
Clear priority at this stage is given to issues relating to the evaluation of CEP applications and the granting of a new or amended CEP. As examples for the changed processes in relation to CEPs it may be mentioned that currently inspections cannot be carried out on site - and that at this time sending paper-based documentation may take a little longer.
Related GMP News
14.10.2026Bioassays in the United States Pharmacopoeia - Two Chapters come into Force in Spring
14.10.2026EDQM Revises Guidance on Electronic Submissions for CEP Applications
07.10.2026CEP 2.0: EDQM Updates Guidance on the Use of Certificates of Suitability
07.10.2026EDQM Updates Guidance on CEP Sister File Applications
23.09.2026IRIS Portal: EMA expands digital Procedure Management
16.09.2026EMA updates Procedural Guidance for Application Preparation